1.Latent Profile Analysis and Influencing Factors of Fear of Progression in Patients with Behçet′s Disease
Lu LI ; Yiyuan AO ; Yeling LIU ; Jingwen WU ; Jinjing LIU ; Wenjie ZHENG
JOURNAL OF RARE DISEASES 2026;5(3):283-291
To explore the latent profile characteristics of fear of progression (FoP) in patients with Behçet′s disease (BD) and analyze its influencing factors. This was a cross-sectional study. By convenience sampling, BD patients attending Peking Union Medical College Hospital from May 2025 to March 2026 were included as study subjects. Data were collected using sociodemographic and disease status questionnaires, the Fear of Progression Questionnaire-Short Form, the Connor-Davidson Resilience Scale, the Perceived Social Support Scale, the Ruminative Response Scale, the Medical Coping Modes Questionnaire, and the Hospital Anxiety and Depression Scale. Latent profile analysis was used to identify FoP profiles, and univariate analysis and multivariate Logistic regression were employed to explore associated influencing factors, and sensitivity analyses were conducted. A total of 221 patients with BD were included in the study. Heterogeneity was observed in their FoP. Latent profile analysis identified three latent classes: the low-fear group-good-adaptation type (68 cases, 30.77%), the moderate-fear group-situational-fluctuation type (110 cases, 49.77%), and the high-fear group-prevalent-worry type (43 cases, 19.46%). The univariate analysis revealed differences among the three patient groups in terms of age, Behçet′s Disease Current Activity Form (BDCAF) score, psychological resilience, perceived social support, rumination, and medical coping styles (including confrontation, avoidance, and resignation)(all FoP in patients with BD exhibits significant population heterogeneity, indicating that individualized and differentiated psychological interventions are warranted in clinical settings to substantially improve patients' overall prognosis and quality of life.
2.Mechanisms of Action of Lenalidomide and Advances in Its Application in Rare Immune-Mediated Inflammatory Diseases
JOURNAL OF RARE DISEASES 2026;5(3):373-381
As a second-generation immunomodulatory imide drug, lenalidomide enhances immunomodulatory effects while reducing neurotoxicity. It synergistically regulates adaptive and innate immune responses through both cereblon (CRBN)-dependent and independent mechanisms, and also exerts multiple biological effects including anti-angiogenesis and anti-fibrosis. Therefore, it has been gradually explored for the treatment of rare immune-mediated inflammatory diseases (IMIDs) in recent years. Existing studies suggest that lenalidomide has potential therapeutic efficacy in diseases such as immunoglobulin G4-related disease and Behçet'sdisease. However, relevant evidence is mainly derived from case reports, and its optimal dosage, applicable populations and long-term safety remain to be further verified. This review summarizes the mechanisms of action of lenalidomide and the research progress of its application in rare IMIDs, with the aim of providing references for future mechanistic exploration and clinical practice.
3.Current disease burden of cellulitis
Minglu GAO ; Jingwen HE ; Chenyue QIU ; Zhihang MIAO ; Lijing ZHU ; Qiong WU ; Ping FENG ; Guangyi WANG ; Guosheng WU
Journal of Public Health and Preventive Medicine 2025;36(5):13-17
Objective To analyze the trend of global cellulitis disease burden from 1990 to 2019, and to provide a theoretical basis for the prevention and control of cellulitis disease. Methods The Global Burden of Disease 2021 (GBD2021) data were collected, and data on the incidence, mortality, and disability-adjusted life year (DALY) of cellulitis were analyzed for each country worldwide. The estimated annual percentage change (EAPC) and age-standardized rate (ASR) were used to estimate the trend change of cellulitis from 1990 to 2021. Results The global burden of cellulitis increased significantly in 2021, with 55.96 million cases, 28.9 million deaths and 876.1 million DALYs, respectively. Incidence and mortality rates were generally higher in males than in females. The incidence and DALYs were higher in high SDI regions, with the highest burden observed in South Asia. In contrast, East Asia exhibited the lowest burden and demonstrated a declining trend. There were significant differences between countries, with India having the highest prevalence, the United States having the highest incidence, and Bahrain having the fastest growing rate.In 2021, China had the lowest age-standardised incidence of cellulitis in the world and the fastest declining age-standardised incidence and age-standardised DALYs. Conclusion The global disease burden of cellulitis is increasing from 1990-2021, and cellulitis remains an an important global public health problem. Targeted preventive meausres should be taken in areas with different economical levels. Men, middle-aged and elderly people, and newborns are the key groups in need of attention and health education.
4.Clinical Practice and Quality Control Strategies for Complex Minimally Invasive Pancreatic Surgery
Jingwen LI ; Zhong WU ; Bing PENG
Journal of Sichuan University (Medical Sciences) 2025;56(4):997-1002
With continuous advancements in the concepts of minimally invasive surgery,pancreatic surgery is gradually undergoing a transformative shift toward minimally invasive approaches.Compared with traditional open surgeries,minimally invasive procedures offer advantages such as reduced trauma,faster recovery,and fewer complications.However,due to the complex anatomical structure of the pancreas and the technical difficulties of surgical procedures,the widespread adoption of minimally invasive pancreatic surgery still faces numerous technical challenges.Currently,laparoscopic pancreaticoduodenectomy(LPD)is primarily performed in large,specialized centers with experienced teams and well-established systems.Given the high technical complexity and associated risks,reducing intraoperative risks and minimizing postoperative complications remain key focuses and major challenges in current research.This review is focused on intraoperative risk control and postoperative complication management in complex minimally invasive pancreatic surgery.We conducted a comprehensive review of recent advances in China and abroad,covering the latest progress in preoperative assessment,intraoperative procedures,complication prevention,quality management,and technological innovation.Furthermore,we discussed potential development directions in minimally invasive pancreatic surgery,including technical refinement,discipline development,procedural standardization,and multi-center collaboration.Our goal is to promote a continued progress toward more standardized,personalized,and intelligent surgical practices—ultimately benefiting a broader population of patients with pancreatic diseases.
5.GSTP1-mediated inhibition of ACSL4-dependent ferroptosis via JNK pathway in DOX-induced cardiomyopathy.
Mingbo WU ; Ye ZHAO ; Dong LI ; Xueli HU ; Jiaojiao ZHOU ; Siyi CHEN ; Xin YANG ; Zegang LI ; Xiaomiao RUAN ; Jingwen YANG ; Wenwu LING
Chinese Medical Journal 2025;138(19):2498-2510
BACKGROUND:
Doxorubicin hydrochloride (DOX) is extensively used in the treatment of various tumors. However, its clinical application is limited due to dose-dependent cardiotoxicity. Currently, few effective strategies exist to mitigate or eliminate DOX-induced cardiomyopathy (DIC). Although ferroptosis is implicated in DIC and its inhibition partially alleviates the condition, the direct targets of DOX in the progression of cardiotoxicity remain unclear. This study aimed to discover the direct targets of DOX in ferroptosis-mediated DIC.
METHODS:
A DOX pulldown assay was performed to identify proteins specifically binding to DOX in murine hearts, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify candidate proteins. A cardiac injury mouse model was established by DOX treatment. Based on this, multiple ferroptosis biomarkers were detected by flow cytometry, quantitative real-time polymerase chain reaction, western blotting, immunochemistry, etc. Besides, specific activator and inhibitor of signaling pathways were applied to illuminate molecular mechanisms.
RESULTS:
Glutathione S-transferase P1 (GSTP1) was identified as a DOX target. GSTP1 activity was inhibited in DOX-treated cardiomyocytes, while its overexpression significantly alleviated DIC. Moreover, GSTP1 overexpression inhibited acyl-CoA synthetase long-chain family member 4 (ACSL4)-dependent ferroptosis. Mechanistically, GSTP1 overexpression suppressed c-Jun N-terminal kinase (JNK) phosphorylation, thereby reducing reactive oxygen species (ROS) production and inhibiting ferroptosis in DIC.
CONCLUSIONS
This study identifies the DOX/GSTP1/JNK axis as a critical pathway mediating ACSL4-dependent ferroptosis in DIC. GSTP1 is highlighted as a potential key mediator of ferroptosis and a promising therapeutic target for DIC.
6.Relationship between blood glucose trajectory during intensive care unit stay and mortality in patients with sepsis-associated acute respiratory distress syndrome.
Yadi YANG ; Hanbing WANG ; Junzhu LIU ; Jingwen WU ; Li ZHOU ; Chunling JIANG
Chinese Critical Care Medicine 2025;37(10):924-930
OBJECTIVE:
To explore the association between blood glucose trajectories within 7 days of intensive care unit (ICU) admission and mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS).
METHODS:
Based on the MIMIC-IV database, sepsis-associated ARDS patients with daily blood glucose monitoring data within 7 days of ICU admission were selected. Blood glucose trajectories were analyzed using group-based trajectory modeling (GBTM), and the optimal number of groups was determined based on the minimum Akaike information criterion (AIC), Bayesian information criterion (BIC), average posterior probability (AvePP), odds of correct classification (OCC), and proportion of group membership (Prop). Baseline characteristics including demographics, comorbidities, severity scores, vital signs, laboratory indicators within the first 24 hours of ICU admission, and treatments were collected. Kaplan-Meier survival curves were used to compare 28-day and 1-year survival across trajectory groups. Multivariate Logistic regression was performed to evaluate the associations between glucose trajectory groups and in-hospital mortality, ICU mortality. The incidence of hypoglycemia within 7 days in the ICU was analyzed among different groups.
RESULTS:
A total of 3 869 patients with sepsis-associated ARDS were included, with a median age of 63.52 (52.13, 73.54) years; 59.6% (2 304/3 869) were male. Based on glucose levels within 7 days, patients were categorized into three groups: persistent hyperglycemia group (glucose maintained at 10.6-13.1 mmol/L, n = 894), moderate glucose group (7.8-8.9 mmol/L, n = 1 452), and low-normal glucose group (6.1-7.0 mmol/L, n = 1 523). There were statistically significant differences in 28-day mortality and 1-year mortality among low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [28-day mortality: 11.42% (174/1 523), 19.83% (288/1 452), 25.50% (228/894), χ 2 = 82.545, P < 0.001; 1-year mortality: 23.31% (355/1 523), 33.75% (490/1 452), 39.49% (353/894), χ 2 = 77.376, P < 0.001]. Kaplan-Meier analysis showed that higher glucose trajectories were associated with significantly lower 28-day and 1-year cumulative survival rates (Log-rank test: χ 2 were 83.221 and 85.022, both P < 0.001). There were statistically significant differences in in-hospital mortality and ICU mortality among the low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [in-hospital mortality: 9.65% (147/1 523), 19.70% (286/1 452), 24.50% (219/894), χ 2 = 102.020, P < 0.001; ICU mortality: 7.22% (110/1 523), 16.05% (233/1 452), 20.13% (180/894), χ 2 = 93.050, P < 0.001]. Logistic regression confirmed that, using the persistent hyperglycemia group as the reference, the low-normal glucose group had significantly lower risks of in-hospital mortality and ICU mortality after multiple factor adjustment. Although the moderate glucose group showed a trend toward lower mortality, the differences were not statistically significant. Using the moderate glucose group as a reference, the low-normal glucose group had 43.1% lower in-hospital mortality [odds ratio (OR) = 0.569, 95% confidence interval (95%CI) was 0.445-0.726, P < 0.001] and 42.0% lower ICU mortality (OR = 0.580, 95%CI was 0.439-0.762, P < 0.001). There was no statistically significant difference in the incidence of hypoglycemia within 7 days of ICU admission among low-normal glucose group, moderate glucose group, and persistent hyperglycemia group [2.82% (43/1 523), 2.69% (39/1 452), 3.02% (27/894), χ 2 = 0.226, P = 0.893].
CONCLUSIONS
Blood glucose trajectories during ICU stay are closely associated with prognosis in patients with sepsis-associated ARDS. Persistent hyperglycemia (10.6-13.1 mmol/L) is linked to significantly higher short- and long-term mortality.
Humans
;
Respiratory Distress Syndrome/etiology*
;
Sepsis/blood*
;
Intensive Care Units
;
Male
;
Female
;
Middle Aged
;
Blood Glucose/metabolism*
;
Hospital Mortality
;
Aged
7.Correlation between long-term statin use and Helicobacter pylori infection in the elderly and the effect of combined eradication therapy on blood lipids
Lumucao BAI ; Yun ZHOU ; Yarong CHEN ; Jingwen YUAN ; Mengru WU ; Xin HU ; Shixiong LIU
Chinese Journal of Geriatrics 2025;44(11):1507-1513
Objective:To investigate the correlation between long-term statin use and Helicobacter pylori( Hp)infection in the elderly, and to compare the effects of rosuvastatin combined with bismuth-containing quadruple therapy for Hp eradication on lipid levels in elderly patients with mixed hyperlipidemia. Methods:A retrospective analysis was conducted on 1 181 elderly patients with hyperlipidemia, cardiovascular and cerebrovascular diseases, and peripheral arterial disease who were treated at the First Hospital of Lanzhou University between March 2019 and December 2023.According to the results of carbon 14 urea breath test(C 14-UBT), the subjects were divided into the Hp infection group and the non- Hp infection group.Multivariate logistic regression methods were used to analyze the correlation between Hp infection and statin use.A prospective case-control analysis was conducted on 109 patients with mixed hyperlipidemia and Hp infection treated during the same period, they were treated with rosuvastatin combined with bismuth-containing quadruple therapy for Hp eradication.The successful eradication people were selected as the eradication group (n=95). Patients with hyperlipidemia and Hp infection unwilling eradication was selected as the control group (n=109), and treated with rosuvastatin.Changes in lipid levels were compared over a consecutive 6-month period. Results:The overall Hp infection rate was 53.94%(637/1 181). Univariate analysis showed that the infection rate in women was higher than in men.Body mass index(BMI), low-density lipoprotein cholesterol(LDL-C), fasting blood glucose(FBG)levels in the Hp(+ )group were higher than in the Hp(-)group.Long-term low-dose aspirin users had a higher infection rate than non-users.The infection rate was lower in statin users than in non-users[42.65%(374/877) vs.55.59%(169/304), χ2=15.234, P<0.001]. Multivariate analysis showed that women had a higher infection risk than men ( OR=1.441, 95% CI: 1.102-1.729, P=0.011). Higher FBG and LDL-C levels increased the risk of Hp infection ( OR=1.406, 95% CI: 1.271-2.286, P<0.001, OR=1.118, 95% CI: 1.017-1.387, P=0.010). Aspirin use increased the risk of Hp infection( OR=1.162, 95% CI: 1.034-1.294, P=0.021), while statin use reduced the risk of Hp infection ( OR=0.177, 95% CI: 0.018-0.311, P<0.001). The Hp eradication rate was 87.16%(95/109). At 1-and 2-months post-eradication, statistically significant differences were observed between the eradication and control groups in LDL-C, total cholesterol(TC), changes from baseline, and target achievement rates(all P<0.05). At 1-month post-eradication, a statistically significant difference was observed in high-density lipoprotein cholesterol(HDL-C) levels between the two groups.Additionally, at both 1-and 2-months post-eradication, significant differences were found in the changes in HDL-C levels from baseline between the eradication group and the control group(all P<0.05). Conclusions:Long-term statin use in the elderly may reduce the risk of Hp infection.Rosuvastatin combined with a standard quadruple therapy does not improve the Hp eradication rates in elderly patients with mixed hyperlipidemia, but it facilitates short-term achievement of cholesterol targets.
8.Investigation of the Mechanism of Atractylodes Ⅰ Inhibiting Colorectal Cancer via the AKT/S6K1 Signaling Pathway
Wei TIAN ; Qiuying YAN ; Jingwen LUO ; Qibiao WU ; Weixing SHEN ; Haibo CHENG ; Changliang XU ; Dongdong SUN
Journal of Nanjing University of Traditional Chinese Medicine 2025;41(8):1037-1046
OBJECTIVE To investigate the pharmacological efficacy and mechanism of action of Atractylenolide Ⅰ(Atr-Ⅰ)in inhibiting colorectal cancer.METHODS Among three active compounds of Atractylodes macrocephala,Atr-Ⅰ exhibited the highest anti-tumor potency by MTT assay.The optimal concentration of Atr-Ⅰ was determined.The effect of Atr-Ⅰ on LoVo cell prolifera-tion was assessed via a clonogenic assay,while its impact on apoptosis and cell cycle progression was evaluated using flow cytometry.The influence of Atr-Ⅰ on the migration and invasion of LoVo cell line was examined through wound healing and Transwell migration assays.Western blot analysis was performed to explore the effects and mechanisms of Atr-Ⅰ on proteins associated with mi-gration,proliferation,and epithelial-mesenchymal transition(EMT)in LoVo cells.The CT26 mouse subcutaneous tumor model was established,and histopathological analysis was conducted using hematoxylin-eosin(HE)staining.Western blot was also used to assess the effects of Atr-Ⅰ on EMT-related proteins in mouse tissues to elucidate underlying mechanisms.RESULTS Atr-Ⅰ significantly reduced colorectal cancer cell viability,with statistically significant differences between treatment and control groups(P<0.05,P<0.01).Atr-Ⅰ induced apoptosis in LoVo cells,with the treatment group showing significant differences compared to the control(P<0.05,P<0.01).Cell cycle analysis revealed that Atr-Ⅰ exerted anti-tumor effects by inducing G2/M phase arrest,with increased G2 phase cell numbers in the LoVo treatment group compared to the control(P<0.05).Wound healing and Transwell migration assays confirmed that Atr-Ⅰ significantly inhibited tumor cell migration and invasion(P<0.05,P<0.01).Western blot analysis demonstra-ted that Atr-Ⅰ specifically suppressed the expression of c-Myc and Bcl-2(P<0.05),as well as cell cycle-related proteins CDK1,Cyclin B1,and Cyclin D1(P<0.05),and angiogenesis-related proteins VEGF and MMP9(P<0.05).Additionally,Atr-Ⅰ down-regulated EMT-related protein N-cadherin and upregulated E-cadherin expression(P<0.05).It also reduced the expression of p-AKT and p-S6K1(P<0.05).CONCLUSION Atr-Ⅰ exhibits potent anti-tumor effects against colorectal cancer,potentially through modulation of the AKT/S6K1 signaling pathway.
9.A analysis of the impact of incorporating molecular subtyping into the FIGO(2023)staging of endometrial cancer on cancer staging
Wenqi LI ; Haixia WU ; Hanbo LI ; Jingwen SI ; Qing ZHANG ; Yan SHEN
Chinese Journal of Clinical and Experimental Pathology 2025;41(11):1454-1461
Purpose To analyze and compare the impact of incorporating molecular classification into the new FI-GO(2023)staging system for endometrial cancer(EC).Methods A retrospective analysis was conducted on 332 ca-ses of EC diagnosed and molecular subtyped by Department of Pathology Tianjin Central Hospital of Gynecology Obstet-rics in 2023.All cases were staged according to the FIGO(2023)staging criteria for EC.Results The median age of the 332 EC patients was 56 years(range:27-76 years).Molecular subtypes included 30 POLE mutation(POLE-mut),80 mismatch repair deficiency(MMRd),194 no specific molecular profile(NSMP),and 28 p53 abnormal(p53abn).Significant differences were observed among the four molecular subtypes regarding age,FIGO stage,patho-logical type,and lymph node metastasis rate(P<0.05).However,no significant differences were found in the depth of myometrial invasion or lymphovascular space invasion.In the POLEmut group,19 cases(63.33%)were of non-ag-gressive histological types and 11(36.67%)were aggressive.After incorporating molecular subtyping,all 11 stage Ⅱ patients were downgraded to stage Ⅰ AmPOLEmut,increasing the proportion of stage Ⅰ patients from 62.07%to 100%.In the p53abn group,9 cases(32.14%)were non-aggressive and 19(67.86%)were aggressive.Molecular integra-tion led to the upstaging of 4 stage Ⅰ patients with myometrial invasion to stage Ⅱ Cmp53abn,increasing the proportion of stage Ⅱ patients from 34.61%to 50%.Conclusion Molecular subtypes p53abn and POLEmut are associated with distinct alterations in EC staging,specifically leading to tumor upstaging or downstaging.Our findings underscore the critical importance of comprehensive molecular subtyping in EC staging,as it refines prognostic risk stratification and provides valuable guidance for adjuvant treatment decisions.
10.Correlation of pan-immune inflammation value with primary IgA nephropathy
Acta Universitatis Medicinalis Anhui 2025;60(7):1333-1339
Objective :
To investigate the correlation between the pan-immune inflammation value (PIV) and clini- cal and pathological features of primary IgA nephropathy (IgAN) ,and to evaluate the clinical significance of PIV in primary IgAN.
Methods:
200 patients with primary IgAN diagnosed by renal biopsy were selected as the re- search subjects.General information,laboratory indicators,pathologic features of renal biopsy,and calculations of platelet to lymphocyte count ratio(PLR) ,neutrophil to lymphocyte count ratio(NLR) ,PIV,and other relevant in- dices about patients were collected.According to the median PIV,subjects were divided into low PIV group (PIV ≤194. 81) and high PIV group ( PIV >194. 81) ,and the clinical and pathological data of the two groups were compared and analyzed.Using Spearman rank correlation analysis and logistic regression analysis,the relationship between PIV and primary IgAN in terms of clinical and pathological aspects was explored.
Results:
There were sta- tistical significance in age,gender,height,hyperuricemia,hemoglobin,absolute neutrophil count (ANC) ,absolute monocytes count,platelet,PLR , NLR , serum uric acid,immunoglobulin G(IgG) ,immunoglobulin A(IgA) / com- plement 3 ( C3) ,and fusion degree of the podocyte foot between the two sets (P<0. 05) .The result of correlation analysis indicated that PIV was positively correlated with ANC,platelet,absolute monocytes count,PLR , NLR , serum creatinine,C3,serum uric acid,and fusion degree of the podocyte foot,but negatively correlated with IgG, IgA/ C3,IgA/ C4.The degree of podocyte foot process fusion was positively correlated with PIV,ANC,total choles- terol,and 24-hour urinary protein to creatinine ratio,and negatively correlated with albumin(ALB) ,IgG,IgA,and IgA/ C3.Logistic regression analysis further indicated that ALB was an independent protective factor for the occur- rence of podocyte foot process fusion in primary IgAN,and PIV was an independent risk factor for the occurrence of podocyte foot process fusion in primary IgAN.
Conclusion
PIV is closely related to the clinical symptoms and pathological lesions of primary IgAN.ALB is an independent protective factor for the occurrence of podocyte foot process fusion in primary IgAN,and PIV is an independent risk factor for the occurrence of podocyte foot process fu- sion in primary IgAN,which can be used as an auxiliary indicator of clinical and pathological results,providing valuable information for risk assessment and treatment plan formulation of primary IgAN.


Result Analysis
Print
Save
E-mail